Compare Vanguard Mega Cap Growth ETF (MGK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Recursion Pharmaceuticals Inc — how do they compare? Vanguard Mega Cap Growth ETF trades at $91.07, while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MGK | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $92.06 | $6.79 |
52-Week Low | $70.70 | $2.84 |
Market Cap | — | $1.78B |
Enterprise Value | — | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $90.79, up 0.87% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF's concentrated portfolio of 69 large-cap U.S. growth stocks, heavily weighted toward technology and consumer discretionary sectors, has delivered robust historical returns. Recent news highlights its low 0.05% expense ratio and potential inclusion of high-profile stocks like SpaceX, reinforcing its appeal for growth-oriented investors seeking mega-cap exposure.
The outlook for MGK remains positive due to its focus on leading growth companies, but risks include high concentration in tech stocks and sensitivity to market volatility. Investors benefit from cost efficiency and historical outperformance, yet must monitor sector-specific downturns and valuation pressures. The ETF is suited for long-term growth strategies with tolerance for drawdowns.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
